Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after b
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... A St. Jude Children,s Research Hospital study found that ... than doubled their risk of developing metabolic syndrome and ... lifestyle. The results appear in the current issue of ... of the 1,598 adult survivors of childhood cancer in ... health risk factors like high blood pressure, abdominal obesity, ...
(Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
(Date:7/27/2014)... has revealed that nicotine and cotinine, a metabolite of ... certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or ... and ultimately ends up in the tobacco smoke. Once ... where it is activated by a variety of enzymes ... revealed that nicotine can partially interfere with the activation ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... April 1, 2008Biotechnology companies are focusing on the ... of current diagnostic tests for cancer, reports Genetic ... cancer therapy forward, a much stronger and targeted ... an article in the April 1 issue of ...
... release is available in Spanish . ... the chemical composition of the rock, etc give rise ... paint coats detachment, dust accumulation, etc. , The treatments ... have been directed, almost exclusively, to preserve the beauty ...
... recent years as the cost and instability of ... major increases in ethanol production. While future plans ... grain ethanol production will lead to further growth ... unintended negative water quality impacts. Currently, U.S. grain-based ...
Cached Biology News:New mineralogical techniques contribute to prevent national heritage damage 2New mineralogical techniques contribute to prevent national heritage damage 3Fueling ethanol production while protecting water quality 2Fueling ethanol production while protecting water quality 3
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
(Date:7/28/2014)... 2014 “2014 Deep Research ... is a professional and in-depth research report ... report introduces Lubricant basic information, including Lubricant ... and industry overview. This research covers the ... as well as global industry analysis covering ...
(Date:7/28/2014)... Junction, MD (PRWEB) July 28, 2014 ... in personalized medicine, will be exhibiting data and research ... year’s International Spine Intervention Society’s (ISIS) 22nd ... 30th-August 3rd, at the Hyatt Regency, in Orlando, Florida. ... the knowledge and clinical competence of physicians who care ...
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3
... it claims will eliminate the hassles of in-house corporate faxing ... orders, companies can buy fax or mail services on a ... case of faxes, phone systems. , ,We see customers looking ... to save money and IT resources, and only pay for ...
... For the past three years, the Internet Marketing Attorney ... this years verdict is in. The recently posted 2004-05 IMA ... over 300 sites in three categories. Several Wisconsin law firms ... Lardner, Durrani Law Firm, Reinhart Boerner, Godfrey & Kahn, Michael ...
... face of Alzheimers Disease was typical of how it robs people ... momentum over time. Independence turned to dependence. At the end, Claude ... of 80, but his memory and even his ability to mumble ... simply forgot how to function. , ,Ive thought of him often ...
Cached Biology Technology:Wisconsin law firm Web sites judged by marketing firm 2Wisconsin law firm Web sites judged by marketing firm 3Wisconsin law firm Web sites judged by marketing firm 4The passing of Ronald Reagan, and other Americans, is a reminder of the promise of stem-cell research 2
... Mouse polyclonal antibody raised against ... Immunogen: SLC22A3 ... a.a) partial recombinant protein with ... Accession Number: NM_021977 ...
...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: